Alimera Sciences Inc (NASDAQ:ALIM) – B. Riley issued their FY2021 EPS estimates for Alimera Sciences in a report released on Tuesday, July 30th, according to Zacks Investment Research. B. Riley analyst A. D’silva anticipates that the biopharmaceutical company will post earnings per share of $0.06 for the year.
A number of other brokerages also recently weighed in on ALIM. ValuEngine raised shares of Alimera Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating on shares of Alimera Sciences in a research note on Friday, June 21st. Craig Hallum assumed coverage on shares of Alimera Sciences in a research note on Tuesday, May 28th. They set a “buy” rating and a $3.00 price target on the stock. Finally, Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Alimera Sciences has an average rating of “Buy” and an average price target of $2.50.
Alimera Sciences (NASDAQ:ALIM) last released its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The firm had revenue of $10.86 million for the quarter, compared to the consensus estimate of $12.97 million.
Several hedge funds have recently bought and sold shares of the business. Knott David M raised its stake in shares of Alimera Sciences by 3.9% during the first quarter. Knott David M now owns 402,901 shares of the biopharmaceutical company’s stock worth $427,000 after acquiring an additional 15,000 shares in the last quarter. B. Riley Wealth Management Inc. raised its stake in shares of Alimera Sciences by 36.7% during the first quarter. B. Riley Wealth Management Inc. now owns 139,302 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 37,396 shares in the last quarter. Columbia Pacific Advisors LLC purchased a new position in shares of Alimera Sciences during the first quarter worth approximately $54,000. Tower Research Capital LLC TRC raised its stake in shares of Alimera Sciences by 32,745.5% during the second quarter. Tower Research Capital LLC TRC now owns 54,852 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 54,685 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Alimera Sciences by 13.1% during the second quarter. Renaissance Technologies LLC now owns 1,128,404 shares of the biopharmaceutical company’s stock worth $1,004,000 after acquiring an additional 130,414 shares in the last quarter. 50.35% of the stock is currently owned by hedge funds and other institutional investors.
Alimera Sciences Company Profile
Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.
Featured Article: What defines an oversold asset?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.